Malecare Prostate Cancer Support Group

Joel Nowak

Denosumab Demonstrates An Increased Time to First Skeletal Event in Men with Metastatic Prostate Cancer vs Zometa

In men with bone metastasis from castration-resistant prostate cancer (CRPC), a monthly subcutaneous injection with denosumab, 120 mg, is superior to Zometa, a multinational group of researchers reported at the American Society of Clinical Oncology annual meeting. The current standard of care is for men with bone metastasis from castration-resistant prostate cancer (CRPC) is to [...]

By |2017-10-19T10:53:43-04:00August 11th, 2010|Advanced Prostate Cancer, bisphosphonates, Drugs & Treatments, Metastases, Uncategorized, Understanding APC|0 Comments
Read More

Carboplatin plus Paclitaxel Therapy after Docetaxel in Men with Metastatic Castrate Resistant Prostate Cancer

UroToday.com published a dual-center study today that confirms that carboplatin and paclitaxel (a taxane product) has an active effect on PSA when used in the treatment of men with castrate resistant prostate cancer (CRPC) after docetaxel (chemotherapy for prostate cancer). […]

By |2017-10-19T10:53:44-04:00August 5th, 2010|Advanced Prostate Cancer, Cabazitaxel, Chemo Therapy, Chemo Therapy Failure, Drugs & Treatments, Uncategorized, Understanding APC|2 Comments
Read More

Should I go on to Hormone Therapy – What about the Risk of Thromboembolic Diseases

(Results from the population-based PCBaSe Sweden) Hormone therapy (ADT) is designed to prevent the manufacturing of testosterone however, testosterone is a very important preventive hormone, especially in the area of heart health. ADT also causes a number of metabolic side-effects including increased body weight, insulin resistance, dyslipidemia, and hyperglycemia. So, how is the risk of [...]

By |2017-10-19T10:53:45-04:00August 1st, 2010|Advanced Prostate Cancer, Drugs & Treatments, Hormone Therapy, Research, Uncategorized, Understanding APC|0 Comments
Read More

Phase II Study of Nitric Oxide for Men with Increasing PSAs After Primary Treatment for Prostate Cancer

Biochemical recurrence of prostate cancer after primary therapy (PSA only) remains a significant problem.   Deciding on the best treatment options for men who have failed primary therapy without documented evidence of metastatic disease remains limited and controversial. Androgen deprivation therapy (ADT), the usual next step for biochemical recurrence does prolong the time to further disease [...]

By |2017-10-19T10:53:45-04:00July 26th, 2010|Advanced Prostate Cancer, Clinical Trials, Clinical Trials, Drugs & Treatments, Research, Technology, Uncategorized, Understanding APC|7 Comments
Read More
Go to Top